BARDA awards Basilea up to $89M for BAL30072

HHS's Biomedical Advanced Research and Development Agency (BARDA) awarded Basilea Pharmaceutica AG (SIX:BSLN) up to $89 million to develop BAL30072. The siderophore sulfactam antibiotic is in Phase I ...